Page last updated: 2024-10-20

taurine and Melanoma

taurine has been researched along with Melanoma in 14 studies

Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)

Research Excerpts

ExcerptRelevanceReference
"The efficacy and tolerability of taurolidine, an antibacterial substance, was evaluated in a phase 2 trial enrolling patients with advanced melanoma."9.15The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. ( Baumann, K; Dummer, R; French, LE; Goldinger, SM; Imhof, L; Röthlisberger, P; Schad, K, 2011)
" In this study, we investigated the antimelanogenic activity of combination of AZ and taurine (Tau) in B16F10 mouse melanoma cells."7.76Effect of combination of taurine and azelaic acid on antimelanogenesis in murine melanoma cells. ( Kim, AK; Yu, JS, 2010)
"This study evaluates whether taurolidine, a novel antibiotic agent, induces murine melanoma cell apoptosis in vitro and in vivo."7.74Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. ( Gong, SL; Liu, LL; Redmond, HP; Sun, BS; Wang, JH, 2007)
"The efficacy and tolerability of taurolidine, an antibacterial substance, was evaluated in a phase 2 trial enrolling patients with advanced melanoma."5.15The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. ( Baumann, K; Dummer, R; French, LE; Goldinger, SM; Imhof, L; Röthlisberger, P; Schad, K, 2011)
" In this study, we investigated the antimelanogenic activity of combination of AZ and taurine (Tau) in B16F10 mouse melanoma cells."3.76Effect of combination of taurine and azelaic acid on antimelanogenesis in murine melanoma cells. ( Kim, AK; Yu, JS, 2010)
"This study evaluates whether taurolidine, a novel antibiotic agent, induces murine melanoma cell apoptosis in vitro and in vivo."3.74Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. ( Gong, SL; Liu, LL; Redmond, HP; Sun, BS; Wang, JH, 2007)
"In human donor samples (4 melanoma-affected eyes, and 14 control eyes; age range, 62-93 years), radiochemical techniques were used to determine the RPE taurine accumulation at various exogenous concentrations."3.72Taurine uptake by human retinal pigment epithelium: implications for the transport of small solutes between the choroid and the outer retina. ( Cunningham, JR; Hillenkamp, J; Hussain, AA; Jackson, TL; Marshall, J, 2004)
"Forty-seven patients with metastatic malignant melanoma took part in a phase II trial of tauromustine (TCNU), a new chlorethylnitrosourea based on the endogenous amino acid taurine."3.67Phase II study of tauromustine in disseminated malignant melanoma. ( Bergh, J; Blomquist, E; Gjedde, SB; Lindegaard-Madsen, E; Mouridsen, HT; Nolte, H, 1989)
"The antitumor activity of 2-[bis-(2-chloroethyl)-amino]ethanesulfonic acid (also referred to here as "taurine mustard" or "taumustine") was evaluated in the murine P388 and L1210 lymphocytic leukemias and in the pigmented and nonpigmented B16 melanoma systems."3.67Modulation by taurine of the toxicity of taumustine, a compound with antitumor activity. ( Fisher, JM; Pierson, HF; Rabinovitz, M, 1985)
"Glycine has been well characterized in spinal cord as an inhibitory neurotransmitter which activates a glycine-gated chloride channel (GlyR) expressed in postsynaptic membranes."2.40Glycine: a new anti-inflammatory immunonutrient. ( Bradford, B; Enomoto, N; Ikejema, K; Rose, ML; Rusyn, I; Schemmer, P; Seabra, V; Stacklewitz, RF; Thurman, RG; Wheeler, MD; Yin, M; Zhong, Z, 1999)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19904 (28.57)18.7374
1990's4 (28.57)18.2507
2000's4 (28.57)29.6817
2010's2 (14.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yu, JS1
Kim, AK1
Imhof, L1
Goldinger, SM1
Baumann, K1
Schad, K1
French, LE1
Röthlisberger, P1
Dummer, R1
Shrayer, DP1
Lukoff, H1
King, T1
Calabresi, P1
Hillenkamp, J1
Hussain, AA1
Jackson, TL1
Cunningham, JR1
Marshall, J1
Sun, BS1
Wang, JH1
Liu, LL1
Gong, SL1
Redmond, HP1
Braumann, C1
Jacobi, CA1
Rogalla, S1
Menenakos, C1
Fuehrer, K1
Trefzer, U1
Hofmann, M1
Gjedde, SB3
Mouridsen, HT3
L-Madsen, E2
Jensen, NV2
Blomquist, E3
Bergh, J3
Söderberg, M2
Wählby, S2
Wheeler, MD1
Ikejema, K1
Enomoto, N1
Stacklewitz, RF1
Seabra, V1
Zhong, Z1
Yin, M1
Schemmer, P1
Rose, ML1
Rusyn, I1
Bradford, B1
Thurman, RG1
Glover, DJ1
Nolte, H1
Lindegaard-Madsen, E1
Smyth, JF1
Gundersen, S1
Renard, J1
Pinedo, HM1
Pierson, HF1
Fisher, JM1
Rabinovitz, M1
Vester, F1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis[NCT01417481]Phase 213 participants (Actual)Interventional2012-03-31Terminated (stopped due to Some of the researchers finished their participation in the study.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Changes in Serum Concentration of Inflammatory Biomarkers (TNF-alpha)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

Interventionlog (percent change) (Mean)
Glycine-0.3908
Placebo0.2035

Changes in Sputum Concentration of Inflammatory Biomarkers (G-CSF)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

Interventionlog (percent change) (Mean)
Glycine-0.0819
Placebo0.1668

Changes in Sputum Concentration of Inflammatory Biomarkers (IL-6)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

Interventionlog (percent change) (Mean)
Glycine-0.00007
Placebo0.1739

Changes in Clinical Data Scores (Other Than Sputum Production, Dyspnea and Global Symptoms)

"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Cough questionnaire scoreAppetite questionnaire scoreEnergy questionnaire scoreBody weightHeightHeart rateRespiratory rateTemperature
Glycine81.189.184.6101.6100.5103.594.8100.0
Placebo89.1132.1111.5103.6100.598.1109.0100.1

Changes in FEV1, FEF25, and FEFmax

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Forced expiratory volume at first second (FEV1)Forced expiratory flow at 25%FVC (FEF25)Maximal forced expiratory flow (FEFmax, PEFR)
Glycine109.7133.9115.3
Placebo91.483.391.2

Changes in Other Spirometric Variables

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Forced vital capacity (FVC)Forced expiratory flow at 75%FVC (FEF75)
Glycine104.1111.8
Placebo100.6108.9

Changes in Pulse Oximetry, FEV1/FVC, and FEF50.

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Peripheral oxygen saturation (SpO2)FEV1/FVCForced expiratory flow at 50%FVC (FEF50)
Glycine105.2105.2115.5
Placebo98.994.993.1

Changes in Score for Sputum Production, Dyspnea and Global Symptoms

"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Sputum questionnaire scoreDyspnea questionnaire scoreTotal questionnaire score
Glycine82.075.677.7
Placebo102.6103.898.7

Changes in Serum Concentration of Inflammatory Biomarkers (Other Than TNF-alpha)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

,
Interventionlog (percent change) (Mean)
MyeloperoxidaseIL-1IL-4IL-6IL-7IL-8IL-12IL-13G-CSFIFN-gammaMCP-1MIP-1beta
Glycine-0.4361-0.16350.29640.00850.0356-0.14660.3203-0.0561-0.07760.3272-0.08360.0330
Placebo-0.2906-0.03520.14700.22550.0819-0.23640.26030.19530.22720.36390.0472-0.0608

Changes in Sputum Concentration of Inflammatory Biomarkers (Other Than IL-6 and G-CSF)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

,
Interventionlog (percent change) (Mean)
MyeloperoxidaseIL-1IL-2IL-4IL-5IL-7IL-8IL-10IL-12IL-13IL-17IFN-gammaMCP-1MIP-1betaTNF-alphaGM-CSF
Glycine0.1294-0.09180.0233-0.01610.24980.0611-0.08240.05490.16750.16300.06800.02480.0042-0.03030.0412-0.0538
Placebo0.0669-0.0102-0.02740.05220.13040.13870.05420.00740.06770.09530.11400.06490.26080.09770.1568-0.0822

Reviews

1 review available for taurine and Melanoma

ArticleYear
Glycine: a new anti-inflammatory immunonutrient.
    Cellular and molecular life sciences : CMLS, 1999, Nov-30, Volume: 56, Issue:9-10

    Topics: Alcohols; Animals; Anti-Inflammatory Agents; Calcium Channels, L-Type; Chloride Channels; Cyclospori

1999

Trials

4 trials available for taurine and Melanoma

ArticleYear
The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study.
    Melanoma research, 2011, Volume: 21, Issue:1

    Topics: Adult; Aged; Anti-Infective Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot

2011
Phase II study of tauromustine in disseminated malignant melanoma.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Melanoma; Middle Aged; Nitrosourea Compoun

1994
Phase I study of tauromustine administered in a weekly schedule.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:13

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Huma

1993
Randomized phase II trial of TCNU versus mitozolomide in malignant melanoma. EORTC Early Clinical Trials Group.
    European journal of cancer & clinical oncology, 1989, Volume: 25, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Ni

1989

Other Studies

9 other studies available for taurine and Melanoma

ArticleYear
Effect of combination of taurine and azelaic acid on antimelanogenesis in murine melanoma cells.
    Journal of biomedical science, 2010, Aug-24, Volume: 17 Suppl 1

    Topics: Animals; Cell Line, Tumor; Dicarboxylic Acids; Drug Combinations; Humans; Melanins; Melanocytes; Mel

2010
The effect of Taurolidine on adherent and floating subpopulations of melanoma cells.
    Anti-cancer drugs, 2003, Volume: 14, Issue:4

    Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Drug Screening Assays, Antitumor; Humans; Mel

2003
Taurine uptake by human retinal pigment epithelium: implications for the transport of small solutes between the choroid and the outer retina.
    Investigative ophthalmology & visual science, 2004, Volume: 45, Issue:12

    Topics: Aged; Aged, 80 and over; Aging; Binding, Competitive; Biological Transport; Carrier Proteins; Case-C

2004
Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins.
    Journal of surgical oncology, 2007, Sep-01, Volume: 96, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Survi

2007
The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model.
    The Journal of surgical research, 2007, Volume: 143, Issue:2

    Topics: Animals; Antineoplastic Agents; Body Weight; Dose-Response Relationship, Drug; Female; Injections, I

2007
New approaches to the chemotherapy of melanoma.
    Oncology (Williston Park, N.Y.), 1991, Volume: 5, Issue:5

    Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto

1991
Phase II study of tauromustine in disseminated malignant melanoma.
    European journal of cancer & clinical oncology, 1989, Volume: 25, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Humans; Melanoma; Middle Aged; Nitr

1989
Modulation by taurine of the toxicity of taumustine, a compound with antitumor activity.
    Journal of the National Cancer Institute, 1985, Volume: 75, Issue:5

    Topics: Animals; Antineoplastic Agents; Cells, Cultured; Female; Leukemia L1210; Leukemia P388; Male; Melano

1985
Amino acid pattern and malignant growth.
    Biochimica et biophysica acta, 1965, Jun-15, Volume: 104, Issue:1

    Topics: Amino Acids; Animals; Antineoplastic Agents; Arginine; Fishes; Histones; In Vitro Techniques; Melano

1965
chemdatabank.com